Condition: HIV-1-infection · Sponsor: University of Nairobi
This clinical trial will address the gap in published data on the effect of dolutegravir (DTG)-associated drug-resistant mutations on viral suppression among people remaining on DTG-based antiretroviral therapy. It will also address the gap in the optimal management strategy for this population.
This description comes directly from the study's public registry record.
Joseph Nkuranga, MBChB, MSc · +254737223988 · dnkuranga@uonbi.ac.ke
Always discuss trial participation with your own doctor first.
| Jaramogi Oginga Odinga Teaching and Referral Hospital | Kisumu, Kenya | Recruiting |
| Bomu Hospital | Mombasa, Kenya | Not Yet Recruiting |
| Kenyatta National Hospital | Nairobi, Kenya | Recruiting |
| Butha-Buthe District Hospital | Butha-Buthe, Lesotho | Not Yet Recruiting |
| Mokhotlong District Hospital | Mokhotlong, Lesotho | Not Yet Recruiting |
| CS Ponta Gea | Beira, Sofala, Mozambique | Not Yet Recruiting |
| CS Machava II | Maputo, Mozambique | Not Yet Recruiting |
| CS Ndlavela | Maputo, Mozambique | Not Yet Recruiting |
| MUHAS Clinical Trial Unit | Dar es Salaam, Tanzania | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06747507